Clinical Study Results
1. STUDY NAME
Title of the Study: A Randomized, Double-Blind Phase 3 Study to
Assess the Efficacy and Safety of ABP 710
Compared to Infliximab in Subjects with Moderate to
Severe Rheumatoid Arthritis
Brief Title: How Did ABP 710 Compare to Infliximab in
Improving Symptoms of Rheumatoid Arthritis?
Protocol Number: 20140111
EU Trial Number: 2014-004704-29
Other Identifiers NCT02937701
(ClinicalTrials.gov):
devorppA
Date of This Summary: 22 May 2019
What does this summary cover?
This summary shows the main results from one clinical study. The results are only
for this study. Other studies may find different results. Researchers and health
authorities look at the results of many studies to decide which medicines work best
and are safest for patients.
2. WHO SPONSORED THIS STUDY?
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 USA
Phone (United States): +1 805-447-1000
Amgen Inc. is the sponsor of the study and manufactured ABP 710, the
investigational medicine in this study. Amgen would like to thank everyone who
participated in this study and feels it is important to share the results of this study.
1